Examkin

Soru

Zorluk: KolayInfectious Diseases

A physician is evaluating the antimicrobial regimen of a patient on the medical floor. The patient, a 58-year-old male, was admitted three days prior for management of severe shortness of breath and a productive cough. At the time of admission, imaging confirmed a left lower lobe consolidation, prompting the initiation of empiric intravenous ceftriaxone and azithromycin. Currently, the patient is clinically stable, breathing comfortably on ambient air, and tolerating his regular diet. He has not had a fever for over 24 hours. Laboratory data today reveals that the initial blood cultures are sterile. However, the admission sputum culture has finalized, demonstrating heavy growth of *Streptococcus pneumoniae*. Susceptibility profiling indicates the isolate is sensitive to penicillin, amoxicillin, levofloxacin, ceftriaxone, and vancomycin. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. Transition to oral amoxicillinCevap
  2. B
    Transition to oral levofloxacin
  3. C
    Continue the current intravenous antibiotic regimen
  4. D
    Transition to oral amoxicillin-clavulanate
  5. E
    Transition to oral linezolid

Cevap

Transitioning to oral amoxicillin is the most appropriate step, as it provides optimal, narrow-spectrum therapy for this specific pathogen.
This patient was admitted with community-acquired pneumonia (CAP) and appropriately started on an empiric broad-spectrum regimen covering both typical and atypical pathogens. He has now achieved clinical stability—evidenced by being afebrile, oxygenating well on ambient air, and tolerating an oral diet—making him eligible for step-down therapy from intravenous to oral antibiotics. Furthermore, his sputum culture definitively identified *Streptococcus pneumoniae* as the sole causative pathogen, and susceptibility testing confirms it is sensitive to penicillin. The core principles of antimicrobial stewardship mandate de-escalating therapy to the narrowest effective agent once a specific pathogen is isolated. For a penicillin-susceptible *S. pneumoniae* isolate, high-dose oral amoxicillin is the preferred narrow-spectrum step-down therapy. Continuing atypical coverage (azithromycin) is no longer necessary since a definitive typical pathogen has been identified.

Adım Adım Çözüm

1
Evaluate the patient's clinical trajectory and readiness for step-down therapy.
The patient is afebrile, hemodynamically stable, off supplemental oxygen, and tolerating oral intake.
Clinical stability indicates the patient is ready to transition from intravenous to oral antibiotic therapy.
2
Analyze the finalized microbiological data to determine the targeted treatment.
The sputum culture definitively isolated Streptococcus pneumoniae that is fully susceptible to penicillin and amoxicillin.
Identifying the specific pathogen allows for de-escalation from empiric broad-spectrum coverage.
3
Apply principles of antimicrobial stewardship to select the ideal definitive oral agent.
Oral amoxicillin is selected as the narrowest effective agent.
Narrow-spectrum therapy minimizes adverse effects, preserves normal flora, and reduces the risk of generating antimicrobial resistance.

Anahtar Kavram

Once a patient with community-acquired pneumonia demonstrates clinical stability and a specific susceptible pathogen is identified, empiric broad-spectrum therapy should be de-escalated to a targeted, narrow-spectrum oral agent.
Tahmini Süre:1m 0s
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru